Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease
Authors:
- Masayoshi TakeuchiMTMasayoshi Takeuchi
- Takashi SatoTSTakashi Sato
- Jun-Ichi TakinoJTJun-Ichi Takino
- Yuka KobayashiYKYuka Kobayashi
- Satomi FurunoSFSatomi Furuno
- Seiji KikuchiSKSeiji Kikuchi
- Sho-Ichi YamagishiSYSho-Ichi Yamagishi
- 1 January 2007
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 69 (6) , 1358-1366
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- ε-Glycation, APP and Aβ in ageing and Alzheimer disease: A hypothesisMedical Hypotheses, 2006
- Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cellsBiochemical and Biophysical Research Communications, 2004
- Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?Medical Hypotheses, 2004
- Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivoMedical Hypotheses, 2004
- Glycation—a sweet tempter for neuronal deathBrain Research Reviews, 2003
- Pentosidine and Nε-(carboxymethyl)-lysine in Alzheimer’s disease and vascular dementiaNeurobiology of Aging, 2002
- Advanced Glycation End Products-Induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor in Bovine Retinal PericytesBiochemical and Biophysical Research Communications, 2002
- Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproductsJournal of Neural Transmission, 1998
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996
- Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapyGeneral Pharmacology: The Vascular System, 1996